Could a constipation drug slow cancer growth? new trial seeks answers

NCT ID NCT07354919

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if axelopran, a drug used for opioid-induced constipation, can slow tumor growth in people with advanced breast, lung, pancreas, or prostate cancer. About 34 adults whose cancer has worsened after standard treatment will take axelopran daily for up to a year. Researchers will check tumor response at 6 weeks and monitor safety and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm exocrine pancreatic carcinoma lung cancer lung neoplasm malignant pancreatic neoplasm metastatic prostate carcinoma neoplasm non-small cell lung carcinoma pancreatic neoplasm prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • HealthPartners Cancer Center at Regions Hospital

    RECRUITING

    Saint Paul, Minnesota, 55101, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • HealthPartners Frauenshuh Cancer Research Center

    RECRUITING

    Saint Louis Park, Minnesota, 55426, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••